Should you buy Sanofi stock now?
No, the technical signal for Sanofi is currently Strong Sell. Sanofi trades at $39.56 as of Oct 7, 2026. The technical analysis shows the following: MACD is negative (bearish trend) at -1.030 with falling momentum (signal: -0.819); RSI is at 27.3 (oversold), which could point to a potential buying opportunity; the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $53.72 points to 35.8% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Sanofi stock?
The average analyst price target for Sanofi is $53.72. The current price is $39.56, which gives an upside of 35.8%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $48.35 and $59.09.
Is Sanofi a dividend stock?
Yes, Sanofi is a dividend stock with a dividend yield of 10.13%. The latest dividend was $2.42 per share. The latest ex-dividend date (traded without the dividend) was May 4, 2026. The payout ratio is 49.3%, which is considered sustainable.
When does Sanofi pay a dividend in 2026?
The next dividend date for Sanofi has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was May 4, 2026. The latest dividend was $2.42 per share with an ex-dividend date of May 4, 2026. The dividend yield is 10.13%. The payout ratio of 49.3% points to a sustainable dividend with room to grow.
What is the risk of Sanofi stock?
Sanofi is rated as a stock in the risk category Conservative. the annual standard deviation is 22.5%, which classifies the stock as Conservative. In addition, an RSI of 27.3 signals oversold (potential bottom).
Is Sanofi overvalued?
No, Sanofi is considered undervalued based on the analyst price target (35.8% upside). Sanofi has the following valuation ratios: a P/E ratio of 22.2 (moderately to highly valued), a P/S ratio of 2.0, a P/B ratio of 1.3. The analyst price target suggests that the stock is undervalued by 35.8%.
Is Sanofi overbought?
No, Sanofi is actually oversold with an RSI of 27.3 (below 30). The technical indicators show: RSI is at 27.3 (below the 30 mark), which actually signals the price is oversold – the opposite of overbought. In addition, the price is 5.1% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish). IMPORTANT: The stock is oversold in a downtrend. A low RSI in a downtrend is NOT a buy signal – the price can keep falling. Wait for a trend reversal before buying.
When is the next Sanofi earnings report?
Sanofi reports its next earnings on October 30, 2026. The stock currently trades at $39.56. With a P/E ratio of 22.2, the market will be watching closely whether earnings meet expectations. The RSI is at 27.3, so the report can reinforce the current technical trend.
Is Sanofi shorted?
Sanofi has minimal short interest of 0.44% of the free float, which is insignificant and points to very limited bearish sentiment.
Are insiders buying Sanofi stock?
Yes, insiders are net buyers of Sanofi – they are buying more shares than they are selling. Over the last 3 months, insiders have made 1 purchases and 0 sales. On a net basis, 13,308,535 $ worth of shares were bought. Across the last 20 reported transactions, the split is 12 purchases and 8 sales, with a net 8,811,651,219 $ sold. Active buyers include Sanofi. Insider buying is generally seen as a positive signal, because management is putting its own money into the company.
Is Sanofi a good stock?
Based on our total score, Sanofi is rated as a good stock with a total score of 60 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 69/100, Quality: 69/100, Momentum: 43/100. In addition: analysts see 35.8% upside to the price target; a dividend of 10.13%; technical signal: Strong Sell. Whether Sanofi is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Sanofi stock?
The outlook for Sanofi based on current data: the average analyst price target is $53.72 (+35.8%); the stock is in a downtrend (below SMA50 and SMA200); the next earnings report is due on Oct 30, 2026, which can move the price; the P/E ratio is 22.2 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Sanofi stock falling?
Sanofi is falling right now. The technical indicators show: the price is 5.1% below the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been buying the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Sanofi go?
The average analyst price target for Sanofi is $53.72, which corresponds to a potential gain of 35.8% from the current price of $39.56. The stock has traded between $39.50 and $49.91 over the last 52 weeks. The price is 20.7% below the 52-week high, which can indicate potential if the underlying fundamentals are intact. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Sanofi fall?
The stock has traded as low as $39.50 over the last 52 weeks — that is 0.2% below the current price of $39.56. The biggest decline (drawdown) in the same period was 20.9% from high to low. Within a year, the price typically swings about ±22.5% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Sanofi do?
**What the company does and how it makes money**
Sanofi is a global healthcare company. It develops, makes and sells medicine. Most of its money comes from treatments for immune system disorders, rare diseases and cancer. Sanofi also makes vaccines, including well-known childh... The company belongs to the Healthcare sector, more specifically the Drug Manufacturers - General industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Sanofi as an investment.
Did Sanofi raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Sanofi. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Sanofi making money or losing money?
Yes, Sanofi is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 8.1% — which is moderate. The operating margin (profit before interest and taxes) is 21.0%. At a P/E ratio of 22.2, you currently pay 22.2 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Sanofi go bankrupt?
The bankruptcy risk of Sanofi is rated as moderate. Altman Z2 (a model for assessing financial distress) is 1.66 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 7 — which is strong. Debt relative to equity is 71% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Sanofi have a lot of debt?
No, Sanofi has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 71%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can Sanofi service its debt? Can service its debt, but it weighs on the company — the interest coverage ratio (how many times earnings can cover interest payments) is 3.9x, and net debt equals 1.3 years of earnings (EBITDA).
